Aberrant DNA methylation in cervical carcinogenesis.

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Persistent high-risk human papillomavirus (HPV) infection is a primary cause of cervical cancer.
• Progression from precancerous lesions to invasive cervical cancer requires additional genetic and epigenetic alterations.
• DNA methylation is an early and frequent molecular event in cervical carcinogenesis.

Purpose of the Study:

• To review DNA methylation patterns within both the HPV and human genomes in cervical carcinogenesis.
• To identify the clinical implications of these methylation patterns.
• To explore the potential of DNA methylation as a biomarker and therapeutic target.

Main Methods:

• Review of existing literature on DNA methylation in HPV and human genomes.
• Analysis of methylation patterns in HPV long control region (LCR) and L1 gene.
• Examination of promoter methylation in tumor suppressor genes (TSGs).

Main Results:

• HPV LCR and L1 gene methylation are common and increase with cervical neoplasm severity.
• Hypermethylation of HPV16 and HPV18 L1 genes in invasive cervical cancers suggests potential as a clinical marker.
• Promoter methylation of TSGs is observed in cervical precursors and cancers, with specific patterns for different cancer subtypes.

Conclusions:

• Methylated HPV genes and TSGs are promising biomarkers for cervical cancer screening and progression monitoring.
• Detection of methylated TSGs in Pap smears could aid in triaging women with HPV infections or precursor lesions.
• Reversion of TSG methylation via demethylating drugs presents a potential therapeutic strategy, pending identification of safe and effective agents.